Navigation Links
Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
Date:9/3/2008

Company Focuses Operations, Updates Zingo Launch Progress and Adlea

Registration Strategy

Conference Call Today at 11:30 am ET

SOUTH SAN FRANCISCO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that the company will restructure operations to focus on commercial and late-stage product development to accelerate its transition to a specialty pharmaceutical pain management company. The company also provided updates on Zingo launch progress, announced the full enrollment of its Phase 3 Adlea clinical trials and provided an update on its Adlea registration strategy.

"Since joining Anesiva in mid-June, I have conducted an extensive review of our programs, priorities and core competencies, which confirms my confidence in the underlying strength of our assets -- namely our people and pipeline," said Michael L. Kranda, president and CEO. "Based on this review we are refining our strategy and restructuring operations to drive the company toward long-term success."

"We believe these actions will expedite our ability to increase the company's value. Specifically, we will continue to strongly support the commercial growth of our first marketed product Zingo(TM), which we recently launched as an analgesic prior to peripheral IV insertions and blood draws in children ages three to 18, and the timely and comprehensive clinical development and commercialization of Adlea(TM), which is in late-stage clinical development for the management of acute pain following orthopedic surgeries. We also intend to pursue the in-licensing of late-stage products that fit within and strengthen our product portfolio," continued Mr. Kranda.

The company is re
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
2. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
3. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
4. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
5. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
6. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
7. Anesiva Defines Regulatory Pathway for Adlea with FDA
8. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
9. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)... , MONTVALE, N.J., Nov. 19 /PRNewswire-First...EMY ) today announced that it has achieved the enr...54, its lead alpha-7 nicotinic receptor agonist, i...ia (CIAS). The Company has randomized 212 patient...payment from its partner Roche. Memory Pharmaceut...
(Date:11/18/2008)...gton Medical Resources (AMR), a,provider of premi...diagnostic,imaging industries, finds that over $1...he U.S. during the third quarter of 2008. Privigen...in (IVIG) and was launched in the first,quarter o...lasma of thousands,of donors and is used to treat...
(Date:11/18/2008)...d, elderly AML patients , , PRINCETON, N.J....today announced that the first patient has been tr...X-351 (Cytarabine:Daunorubicin) Liposome Injection...ukemia (AML). , , The first patient was enr...llege of Cornell University and New York Presbyte...
(Date:11/13/2008)...ut Risk of Heart Attacks, Deaths, RESTON, Va., No...sease,is the leading cause of death among American...ons of dollars and causing untold suffering. Now,t... - even among those who,weren,t thought to be at r...le could cut their risk of a,heart attack, stroke ...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Seniors Can Be Heartened by New Study on Statins 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 1Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 3DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 1DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 2DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 3Oral Contraceptives Cut Ovarian Cancer Risk 10111 1Oral Contraceptives Cut Ovarian Cancer Risk 10111 2Oral Contraceptives Cut Ovarian Cancer Risk 10111 3Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 1Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 2Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 3
..., Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc....e recent Phase II proof of,concept clinical trial ...nical trial evaluating ACAPODENE(R) (toremifene ci...fects of androgen,deprivation therapy (ADT) will b... the American Society of Clinical Oncology being,h...
...RSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ -...nnounce results from the,Phase 1 trial of its patc...arkets open tomorrow. A conference call and live,w...rrow to discuss,the results. , Conference Call Det...May 25, 2007 at 8:30,a.m. Eastern Time via phone, ...
Other Medicine Technology:GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:11/21/2008)...about future antibiotic resistance from widespread...ws) -- People with moderate to severe chronic obst...duce the frequency of exacerbations through a regu... says. , The study, published in the first iss...atory and Critical Care Medicine , found that twic...
(Date:11/21/2008)...wswire-USNewswire/ -- New research at West Virgin...pitless tobacco product aimed at young adults is c... Reynolds, Camel Snus - touted as a socially accep...ngly high levels of nicotine. , , "Camel Sn...oducts," said Bruce Adkins of the state Division o...
(Date:11/21/2008)...- The general membership of the Medical,Advertisi...als at their Annual,Awards Dinner to be held Febr...Lifetime Achievement Award will also be given. , ...ing Hall of Fame are: , Ronald Pantello, who be...n,at Sudler & Hennessey. In 1980 he left Sudl...
(Date:11/21/2008)... increases production of neural stem cells , ...riments in mice, exercise appears to reverse the d...ly seen with aging, Taiwanese researchers report. ...ility to stave off aging appears to be due to exer...essential for the production of new brain cells. ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Exercise Keeps the Brain Young 2
...er Hewlett Professor of Internal Medicine at the U...e saying// that the qualities of service provided ... compromised. The study was mainly conducted to su... work hours implemented since 2003. The findings w...
...al Economy Research Institute at the University of...anies that are responsible for air pollution//. Th...rporate companies are listed as an important sourc... of hundreds of chemicals from industrial faciliti...
...as legalized abortion. But the rivals of the new S...eme Court. The new law is on its way to go// in to...d to decide the fate of the law. The opponents of ... 19 on petitions designed to put the law on the No...
...on of common genes linked to cancer is expected to...al Cancer Institute report that huge resources// a... genetic variants that would increase the suscepti... that there are a number of problems when doing su...
Other Medicine News:
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
...ted Clinical Applications:, ,Cool Aerosol Therapy...th open system devices such as aerosol masks, face...de only limited FIO2 and limited flow. The design ...dental dilution with room air or high FIO2 due to ...
...w PARI TREK™ Compact Compressor is for activ...ts anywhere and everywhere. The compressor is smal...ower source optionsworldwide AC compatibility (100...rmit patients the freedom to take aerosol treatmen...
...ucing Quieter Compressed Air., ,Allied Healthcare...so much quieter than other air compressors that yo... too. The PCS 414 features a durable, mar-resistan..., the unit weighs only 26.5 pounds. The PCS 414 ha...
Medicine Products: